Development of SLE Among "potential SLE" Patients Seen in Consultation: Long-term Follow-up
Overview
Affiliations
Objective: To identify factors associated with development of systemic lupus erythematosus (SLE) among patients evaluated at a tertiary care Lupus Center for potential SLE.
Methods: We identified patients first seen at the Brigham and Women's Hospital Lupus Center between 1 January 1992 and 31 December 2012 and thought to have potential SLE by a board-certified rheumatologist. All had 1-3 SLE ACR criteria at initial visit and > 2 follow-up visits ≥ 3 months apart. We reviewed medical records through 15 May 2013 for: SLE signs and symptoms, autoimmune serologies, prescriptions and diagnoses by board-certified rheumatologists. Bivariable analyses and multivariable logistic regression models were used to identify independent predictors of developing SLE.
Results: Two hundred and sixty four patients met inclusion criteria. At initial visit, mean age was 39.2 (SD 12.4) years, 94% were female and 67% white. Mean number of SLE ACR criteria was 2.7 (SD 1.0) and 88% were antinuclear antibody (ANA) positive at initial consultation. Mean follow-up time was 6.3 (SD 4.3) years and 67% were prescribed hydroxychloroquine in follow-up. At most recent visit, 56 (21%) had been diagnosed with SLE; 47 (18%) were thought not to have SLE and 161 (61%) were still considered to have potential SLE. In multivariable regression models, oral ulcers (OR 2.40, 95% CI 1.03-5.58), anti-dsDNA (OR 2.59, 95% CI 1.25-5.35) and baseline proteinuria or cellular casts (OR 16.20, 95% CI 1.63-161.02) were independent predictors of developing SLE. The most common other final diagnoses included fibromyalgia, Sjögren's syndrome, mixed connective tissue disease and cutaneous lupus.
Conclusion: Among patients with potential SLE at initial consultation, 21% were diagnosed with definite SLE within 6.3 years. Oral ulcers, anti-dsDNA and proteinuria or cellular casts were independent predictors of developing definite SLE. A better means of accurately identifying those who will develop SLE among those presenting with potential disease is necessary.
Li X, Li Y, Huang C, Liu J, Liu R, Zhang Z Ann Med. 2024; 56(1):2392882.
PMID: 39155852 PMC: 11334742. DOI: 10.1080/07853890.2024.2392882.
Genetic load in incomplete lupus erythematosus.
Slief M, Kheir J, Smith M, Mowery C, Macwana S, DeJager W Lupus Sci Med. 2023; 10(1.
PMID: 36599633 PMC: 9815005. DOI: 10.1136/lupus-2022-000843.
Calderon L, Pope J Front Immunol. 2022; 13:869172.
PMID: 35603174 PMC: 9118990. DOI: 10.3389/fimmu.2022.869172.
Sternhagen E, Bettendorf B, Lenert A, Lenert P J Inflamm Res. 2022; 15:1133-1145.
PMID: 35210816 PMC: 8863324. DOI: 10.2147/JIR.S275043.
Differentiating between UCTD and early-stage SLE: from definitions to clinical approach.
Sciascia S, Roccatello D, Radin M, Parodis I, Yazdany J, Pons-Estel G Nat Rev Rheumatol. 2021; 18(1):9-21.
PMID: 34764455 DOI: 10.1038/s41584-021-00710-2.